Inside out: TNFa-RII and sexualized drug use in acute HIV predicts persistent depressive symptoms despite antiretroviral therapy

由内而外:急性 HIV 感染者中 TNFα-RII 和性药物滥用预示着即使接受抗逆转录病毒治疗,抑郁症状仍会持续存在

阅读:1

Abstract

OBJECTIVE: Although pathophysiologic alterations during acute HIV infection (AHI) may have long-term neuropsychiatric consequences, scant research has examined biobehavioral predictors of distinct depressive symptom trajectories from AHI through suppressive anti-retroviral therapy (ART), despite the fact that depressive symptoms have been associated with poorer adherence to ART and overall quality of life. METHODS: This analysis utilized data from the RV254/SEARCH010 Cohort, a large, well-characterized AHI cohort in Bangkok, Thailand. Longitudinal hierarchal density-based spatial clustering with uniform manifold approximation and projection was used to examine depressive symptom trajectories from AHI through 96 weeks of suppressive ART. Logistic regressions examined the immunologic and behavioral correlates of persistently high (versus low) depressive symptom trajectories. RESULTS: Participants (N = 502) were between the ages of 18 and 70, with a mean age of 27.7 (SD 7.4). The sample was predominantly male (98 %, n = 494). Three depressive symptom trajectories emerged: Cluster 1 (n = 257, 51 %) persistently high, Cluster 2 (n = 61, 12 %) transient, and Cluster 3 (n = 184, 37 %) persistently low. There were greater odds of persistently high (versus low) depressive symptoms for every log(10)copies/mL increase in plasma viral load (Odds Ratio [OR] = 1.27; 95 % Confidence Interval [CI] = 0.99-3.35) and sTNF-αRII (OR = 1.23, 95 % CI = 1.04, 1.45) at baseline. Recent amyl nitrite use also increased risk (OR = 2.39; 95 % CI = 1.17, 4.88). CONCLUSIONS: Viral load, inflammation and substance use may be viable targets for reducing risk for depressive disorders in people with HIV, even in its earliest stages.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。